NASDAQ:NYMX - Nymox Pharmaceutical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.71 +0.24 (+9.72 %)
(As of 02/18/2019 10:59 AM ET)
Previous Close$2.47
Today's Range$2.37 - $2.72
52-Week Range$1.25 - $4.60
Volume101,919 shs
Average Volume85,056 shs
Market Capitalization$155.03 million
P/E RatioN/A
Dividend YieldN/A
Beta1.98
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.

Receive NYMX News and Ratings via Email

Sign-up to receive the latest news and ratings for NYMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NYMX
CUSIPN/A
Phone800-936-9669

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$220,000.00
Book Value($0.02) per share

Profitability

Net Income$-13,420,000.00
Net Margins-2,909.61%

Miscellaneous

EmployeesN/A
Market Cap$155.03 million
OptionableOptionable

Nymox Pharmaceutical (NASDAQ:NYMX) Frequently Asked Questions

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Corp (NASDAQ:NYMX) issued its earnings results on Friday, November, 14th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The biopharmaceutical company had revenue of $0.08 million for the quarter. Nymox Pharmaceutical had a negative net margin of 2,909.61% and a negative return on equity of 863.35%. View Nymox Pharmaceutical's Earnings History.

When is Nymox Pharmaceutical's next earnings date?

Nymox Pharmaceutical is scheduled to release their next quarterly earnings announcement on Friday, March 29th 2019. View Earnings Estimates for Nymox Pharmaceutical.

Has Nymox Pharmaceutical been receiving favorable news coverage?

Media stories about NYMX stock have been trending somewhat positive this week, according to InfoTrie. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Nymox Pharmaceutical earned a coverage optimism score of 1.6 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.

Who are some of Nymox Pharmaceutical's key competitors?

Who are Nymox Pharmaceutical's key executives?

Nymox Pharmaceutical's management team includes the folowing people:
  • Dr. Paul Averback, Founder, Chairman, CEO & Pres (Age 68)
  • Mr. Erik Danielsen, Chief Financial Officer (Age 56)
  • Mr. Randall J. Lanham, Gen. Counsel, Sec. & Director (Age 55)
  • Dr. Judith Fitzpatrick Ph.D., Exec. (Age 70)
  • Dr. Suresh Kalbag M.D., Director of CMC Operations

Who are Nymox Pharmaceutical's major shareholders?

Nymox Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional investors include Northern Trust Corp (0.49%), Bank of America Corp DE (0.26%), Wedbush Securities Inc. (0.25%), Geode Capital Management LLC (0.23%), Rhumbline Advisers (0.07%) and Private Advisor Group LLC (0.07%). Company insiders that own Nymox Pharmaceutical stock include Erik Danielsen, James George Robinson, Paul Averback and Randall J Lanham. View Institutional Ownership Trends for Nymox Pharmaceutical.

Which institutional investors are selling Nymox Pharmaceutical stock?

NYMX stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Nymox Pharmaceutical.

Which institutional investors are buying Nymox Pharmaceutical stock?

NYMX stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Private Advisor Group LLC, Brown Advisory Inc., Rhumbline Advisers, Geode Capital Management LLC and Northern Trust Corp. Company insiders that have bought Nymox Pharmaceutical stock in the last two years include Erik Danielsen, James George Robinson and Randall J Lanham. View Insider Buying and Selling for Nymox Pharmaceutical.

How do I buy shares of Nymox Pharmaceutical?

Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nymox Pharmaceutical's stock price today?

One share of NYMX stock can currently be purchased for approximately $2.71.

How big of a company is Nymox Pharmaceutical?

Nymox Pharmaceutical has a market capitalization of $155.03 million and generates $220,000.00 in revenue each year.

What is Nymox Pharmaceutical's official website?

The official website for Nymox Pharmaceutical is http://www.nymox.com.

How can I contact Nymox Pharmaceutical?

Nymox Pharmaceutical's mailing address is 9900 CAVENDISH BLVD. SUITE 306, ST. LAURENT A8, H4M 2V2. The biopharmaceutical company can be reached via phone at 800-936-9669 or via email at [email protected]


MarketBeat Community Rating for Nymox Pharmaceutical (NASDAQ NYMX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  96 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  194
MarketBeat's community ratings are surveys of what our community members think about Nymox Pharmaceutical and other stocks. Vote "Outperform" if you believe NYMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NYMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Featured Article: Straddles

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel